National Institutes of Health
American Academy of Ophthalmology
Laabs’ foundation and Aura Biosciences advance efforts to develop new and better therapies to treat rare cancer patients. Aura Biosciences is hoping to improve the options for future ocular melanoma patients.
Listen to this podcast to learn more about how Aura CEO Eli de los Pinos built the company from the ground up around viral-like synthetic nanoparticles that are closely related to wild type viruses in structure and behavior but lack any viral DNA.
Wall Street Journal
JP Morgan, San Francisco
Harvard Medical School
Boston Business Journal